Table 1.
Patient demographics and baseline characteristics (ITT population)
| Characteristic | Delafloxacin, N = 331 | Vancomycin + aztreonam, N = 329 |
|---|---|---|
| Age (years), mean ± SD (range) | 46.3 ±13.91 (18–94) | 45.3 ±14.4 (19–90) |
| Age category (years), n (%) | ||
| ≤65 | 309 (93.4) | 309 (93.9) |
| >65 | 22 (6.6) | 20 (6.1) |
| >75 | 7 (2.1) | 10 (3.0) |
| Men, n (%) | 206 (62.2) | 209 (63.5) |
| Race, n (%) | ||
| white | 297 (89.7) | 304 (92.4) |
| black or African American | 27 (8.2) | 19 (5.8) |
| American Indian or Alaska native | 5 (1.5) | 2 (0.6) |
| Asian | 1 (0.3) | 1 (0.3) |
| native Hawaiian or other Pacific Islander | 1 (0.3) | 2 (0.6) |
| other | 0 | 1 (0.3) |
| Ethnicity, n (%) | ||
| Hispanic or Latino | 101 (30.5) | 103 (31.3) |
| Region, n (%) | ||
| Europe | 63 (19.0) | 55 (16.7) |
| North America | 268 (81.0) | 274 (83.3) |
| BMI (kg/m2), mean ± SD | 28.4 ± 6.42 | 27.9 ±6.36 |
| BMI ≥30 kg/m2, n (%) | 120 (36.3) | 94 (28.6) |
| Diabetes, n (%) | 30 (9.1) | 27 (8.2) |
| Prior antibiotic use, n (%) | 52 (15.7) | 71 (21.6) |
| Baseline pain score, mean ± SD | 7.9 (2.0) | 7.8 (2.2) |
| Duration of exposure | ||
| n | 324 | 326 |
| mean (SD) days | 6.18 (2.81) | 6.15 (2.62) |
| median days | 5.00 | 5.50 |
| min, max days | 0.5, 14.0 | 0.5, 14.0 |